BTIG Thinks Vapotherm’s Stock is Going to Recover

BTIG analyst Marie Thibault reiterated a Buy rating on Vapotherm (VAPOResearch Report) yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $21.63, close to its 52-week low of $20.29.

According to, Thibault is a 5-star analyst with an average return of 70.8% and a 58.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vapotherm with a $40.33 average price target.

See today’s analyst top recommended stocks >>

Based on Vapotherm’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $40.91 million and GAAP net loss of $17.18 million. In comparison, last year the company earned revenue of $13.01 million and had a GAAP net loss of $12.45 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. It offers Hi-VNI Technology, a product which delivers noninvasive ventilator support by providing heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. Its products include Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, Precision Flow Heliox, Vapotherm Transfer Unit 2.0, Q50 compressor, Disposable Patient Circuit, Nitric Oxidie Disposable Patient Circuit, Nasal Cannulas, Tracheostomy Adapter and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.